MEG‑3‑mediated Wnt/β‑catenin signaling pathway controls the inhibition of tunicamycin‑mediated viability in glioblastoma

Cui,Xiangyu; Sun,Dezhou; Shen,Bin; Wang,Xin

doi:10.3892/ol.2018.9048

MEG‑3‑mediated Wnt/β‑catenin signaling pathway controls the inhibition of tunicamycin‑mediated viability in glioblastoma

Authors:
- Xiangyu Cui
- Dezhou Sun
- Bin Shen
- Xin Wang
View Affiliations

Affiliations: Department of Neurosurgery, Dezhou People's Hospital, Dezhou, Shandong 253045, P.R. China
Published online on: June 28, 2018 https://doi.org/10.3892/ol.2018.9048
Pages: 2797-2804
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma is the most common primary brain carcinoma and leads to a poor survival rate of patients worldwide. Results of previous studies have suggested that tunicamycin may inhibit aggressiveness by promoting apoptosis of glioblastoma cells. In the present study, the effects of tunicamycin and its potential molecular mechanisms underlying the viability and aggressiveness of glioblastoma cells were investigated. Western blot analysis, the reverse transcription‑quantitative polymerase chain reaction, immunohistochemistry, apoptosis assays and immunofluorescence were employed to examine the effects of tunicamycin on apoptosis, viability, aggressiveness and cell cycle arrest of glioblastoma cells by downregulation of the expression levels of fibronectin and epithelial cadherin. In vitro experiments demonstrated that tunicamycin significantly inhibited the viability, migration and invasion of glioblastoma cells. Results demonstrated that tunicamycin administration promoted apoptosis of glioblastoma cells through the upregulation of poly(ADP‑ribose) polymerase and caspase‑9. Cell cycle assays revealed that tunicamycin suppressed the proliferation of, and induced cell cycle arrest at S phase in, glioblastoma cells. Additionally, tunicamycin increased the expression of maternally expressed gene‑3 (MEG‑3) and wingless/integrated (Wnt)/β‑catenin in glioblastoma cells. Results also indicated that tunicamycin administration promoted the Wnt/β‑catenin signaling pathway in glioblastoma cells. Knockdown of MEG‑3 inhibited tunicamycin‑mediated downregulation of the Wnt/β‑catenin signaling pathway, which was inhibited further by tunicamycin‑mediated inhibition of viability and aggressiveness in glioblastoma. In vivo assays demonstrated that tunicamycin treatment significantly inhibited tumor viability and promoted apoptosis, which further led to an increased survival rate of tumor‑bearing mice compared with that of the control group. In conclusion, these results indicate that tunicamycin may inhibit the viability and aggressiveness by regulating MEG‑3‑mediated Wnt/β‑catenin signaling, suggesting that tunicamycin may be a potential anticancer agent for glioblastoma therapy.

View Figures

View References

1	Preusser M, Berghoff AS, Wick W and Weller M: Clinical Neuropathology mini-review 6–2015: PD-L1: Emerging biomarker in glioblastoma? Clin Neuropathol. 34:313–321. 2015. View Article : Google Scholar : PubMed/NCBI
2	Nguyen HS, Doan N, Gelsomino M, Shabani S, Mueller W and Zaidat OO: Coincidence of an anterior cerebral artery aneurysm and a glioblastoma: Case report and review of literature. Int Med Case Rep J. 8:295–299. 2015. View Article : Google Scholar : PubMed/NCBI
3	Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG and Zhang M: Nanoparticle-mediated target delivery of TRAIL as gene therapy for glioblastoma. Adv Healthc Mater. 4:2719–2726. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hariri OR, Quadri SA, Farr S, Gupta R, Bieber AJ, Dyurgerova A, Corsino C, Miulli D and Siddiqi J: Third ventricular glioblastoma multiforme: Case report and literature review. J Neurol Surg Rep. 76:e227–e232. 2015. View Article : Google Scholar : PubMed/NCBI
5	Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, et al: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 4:101–112. 2005.PubMed/NCBI
6	Delfino KR, Serao NV, Southey BR and Rodriguez-Zas SL: Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics. 8:173–183. 2011.PubMed/NCBI
7	Koekkoek JA, Postma TJ, Heimans JJ, Reijneveld JC and Taphoorn MJ: Antiepileptic drug treatment in the end-of-life phase of glioma patients: A feasibility study. Support Care Cancer. 24:1633–1638. 2015. View Article : Google Scholar : PubMed/NCBI
8	Thuy MN, Kam JK, Lee GC, Tao PL, Ling DQ, Cheng M, Goh SK, Papachristos AJ, Shukla L, Wall KL, et al: A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools. J Clin Neurosci. 22:785–799. 2015. View Article : Google Scholar : PubMed/NCBI
9	Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD and Hersey P: Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67:5880–5888. 2007. View Article : Google Scholar : PubMed/NCBI
10	Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T and Sakai T: Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 65:6364–6370. 2005. View Article : Google Scholar : PubMed/NCBI
11	Giordano E, Davalos A, Nicod N and Visioli F: Hydroxytyrosol attenuates tunicamycin-induced endoplasmic reticulum stress in human hepatocarcinoma cells. Mol Nutr Food Res. 58:954–962. 2014. View Article : Google Scholar : PubMed/NCBI
12	Carlisle RE, Brimble E, Werner KE, Cruz GL, Ask K, Ingram AJ and Dickhout JG: 4-Phenylbutyrate inhibits tunicamycin-induced acute kidney injury via CHOP/GADD153 repression. PLoS One. 9:e846632014. View Article : Google Scholar : PubMed/NCBI
13	Kim SH, Shin HY, Kim YS, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells. Anticancer Res. 34:4857–4868. 2014.PubMed/NCBI
14	Hasegawa A, Osuga Y, Hirota Y, Hamasaki K, Kodama A, Harada M, Tajima T, Takemura Y, Hirata T, Yoshino O, et al: Tunicamycin enhances the apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand in endometriotic stromal cells. Hum Reprod. 24:408–414. 2009. View Article : Google Scholar : PubMed/NCBI
15	Xing Y, Ge Y, Liu C, Zhang X, Jiang J and Wei Y: ER stress inducer tunicamycin suppresses the self-renewal of glioma-initiating cell partly through inhibiting Sox2 translation. Oncotarget. 7:36395–36406. 2016. View Article : Google Scholar : PubMed/NCBI
16	Bai FL, Yu YH, Tian H, Ren GP, Wang H, Zhou B, Han XH, Yu QZ and Li DS: Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther. 15:1226–1238. 2014. View Article : Google Scholar : PubMed/NCBI
17	Suchorska B, Albert NL and Tonn JC: Usefulness of PET imaging to guide treatment options in gliomas. Curr Treat Options Neurol. 18:42016. View Article : Google Scholar : PubMed/NCBI
18	Broggini T, Wustner M, Harms C, Stange L, Blaes J, Thomé C, Harms U, Mueller S, Weiler M, Wick W, et al: NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment. Cancer Lett. 380:568–576. 2016. View Article : Google Scholar : PubMed/NCBI
19	Mesti T and Ocvirk J: Malignant gliomas: Old and new systemic treatment approaches. Radiol Oncol. 50:129–138. 2016. View Article : Google Scholar : PubMed/NCBI
20	Kunz M, Nachbichler SB, Ertl L, Fesl G, Egensperger R, Niyazi M, Schmid I, Tonn JC, Peraud A and Kreth FW: Early treatment of complex located pediatric low-grade gliomas using iodine-125 brachytherapy alone or in combination with microsurgery. Cancer Med. 5:442–453. 2016. View Article : Google Scholar : PubMed/NCBI
21	Miyake H, Hara I, Arakawa S and Kamidono S: Stress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells. J Cell Biochem. 77:396–408. 2000. View Article : Google Scholar : PubMed/NCBI
22	von dem Knesebeck A, Felsberg J, Waha A, Waha A, Hartmann W, Scheffler B, Glas M, Hammes J, Mikeska T, Yan PS, et al: RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. Neoplasia. 14:526–534. 2012. View Article : Google Scholar : PubMed/NCBI
23	Johnson GG, White MC and Grimaldi M: Stressed to death: Targeting endoplasmic reticulum stress response induced apoptosis in gliomas. Curr Pharm Des. 17:284–292. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, et al: Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 16:33–39. 2006.PubMed/NCBI
25	Davis MI, Pragani R, Fox JT, Shen M, Parmar K, Gaudiano EF, Liu L, Tanega C, McGee L, Hall MD, et al: Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models. J Biol Chem. 29:24628–24640. 2016. View Article : Google Scholar
26	Li J, Zhou D, Wang Z, Tan L, Zhou Y and Sheng X: Reversal effect of 5-aza-2-deoxycytidine on the maternally expressed gene 3 promoter hypermethylation and its inhibitory effect on the proliferation of epithelial ovarian cancer cells. Zhonghua Zhong Liu Za Zhi. 37:324–329. 2015.(In Chinese). PubMed/NCBI
27	Yan-Hua L, Xiang-Lei L, Hong L and Jian-Jun W: Long noncoding ribonucleic acids maternally expressed gene 3 inhibits lung cancer tumor progression through downregulation of MYC. Ind J Cancer. 52 Suppl 3:E190–E193. 2015. View Article : Google Scholar
28	Lv D, Sun R, Yu Q and Zhang X: The long non-coding RNA maternally expressed gene 3 activates p53 and is downregulated in esophageal squamous cell cancer. Tumour Biol. 2016.(Epub ahead of print). View Article : Google Scholar
29	Sareddy GR, Challa S, Panigrahi M and Babu PP: Wnt/β-catenin/Tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem Res. 34:1278–1288. 2009. View Article : Google Scholar : PubMed/NCBI
30	Abla AA, Turner JD and Sanai N: FoxM1 is vital in the Wnt/β-catenin signaling pathogenesis of gliomas. World Neurosurg. 77:594–596. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wu W, Tian Y, Wan H, Song Y, Li J and Zhang L: The expressions of Wnt/β-catenin pathway-related components in brainstem gliomas. Can J Neurol Sc. 40:355–360. 2013. View Article : Google Scholar
32	Lu P, Wang Y, Liu X, Wang H, Zhang X, Wang K, Wang Q and Hu R: Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/beta-catenin signaling. Med Oncol. 33:662016. View Article : Google Scholar : PubMed/NCBI